CSF CXCL13 in Lyme Disease

In Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection), published studies report higher levels of CSF CXCL13, also described as B-cell chemoattractant, than in Non-neuroborreliosis controls. Clinically, it has been associated with neuroborreliosis — high specificity. This entry summarises Rupprecht et al. 2005. Group-level associations like this do not translate into an individual diagnostic cut-off.

↑ ElevatedCSF

Summary

Direction in Lyme Disease↑ Elevated — higher than in the comparison group
CategoryCSF
Also described asB-cell chemoattractant
Compared againstNon-NB controls (Non-neuroborreliosis controls)
Associated symptomsNeuroborreliosis — high specificity
Test typeTissue / pathology test
SourceRupprecht et al. 2005 — doi:10.1212/01.wnl.0000185296.27976.4f
Condition atlasLyme Disease Biomarker Atlas

Trials, interventions and tests

Commercial test availability

CSF CXCL13 (Neuroborreliosis) — specialty laboratory test. Specialty CSF send-out for Lyme neuroborreliosis.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related CSF markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is CSF CXCL13 high or low in Lyme Disease?

Elevated. Studies summarised in the OSMF atlas report higher CSF CXCL13 in Lyme Disease than in Non-neuroborreliosis controls. Source: Rupprecht et al. 2005.

What symptoms is CSF CXCL13 associated with in Lyme Disease?

The cited literature associates this marker with Neuroborreliosis — high specificity. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures CSF CXCL13?

It is measured as a tissue / pathology test. Commercial laboratories such as Euroimmun (specialty) list an orderable assay.

Is one abnormal CSF CXCL13 result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. CSF CXCL13 findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). CSF CXCL13 in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/lyme/csf-cxcl13.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.